Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide

Purpose: Programmed cell death ligand-1 (PD-L1)/programmed cell death-1 (PD-1) blockade has been unsuccessful in prostate cancer, with poor immunogenicity and subsequent low PD-L1 expression in prostate cancer being proposed as an explanation. However, recent studies indicate that a subset of prostate cancer may express significant levels of PD-L1. Furthermore, the androgen antagonist enzalutamide has been shown to upregulate PD-L1 expression in prostate cancer preclinical models. In this study, we evaluated the effect of neoadjuvant androgen deprivation therapy with abiraterone acetate plus prednisone and leuprolide (Neo-AAPL) on PD-L1 expression in prostate cancer. Experimental Design: Radical prostatectomy (RP) tissues were collected from 44 patients with intermediate- to high-risk prostate cancer who underwent RP after Neo-AAPL treatment. Untreated prostate cancer tissues were collected from 130 patients, including 44 matched controls for the Neo-AAPL cases. Tumor PD-L1 expression was detected by IHC using validated anti-PD-L1 antibodies. Tumor-infiltrating CD8+ cells were analyzed in trial cases and matched controls. Expression of DNA mismatch repair genes was examined in PD-L1–positive tumors. Results: Neo-AAPL–treated tumors showed a trend toward decreased PD-L1 positivity compared with matched controls (7% vs. 21% having ≥1% positive tumor cells; P = 0.062). Treated tumors also harbored significantly fewer tumor-infiltrating CD8+ cells (P = 0.029). In 130 untreated prostate cancers, African American ethnicity, elevated serum PSA, and small prostate independently predicted tumor PD-L1 positivity. Loss of MSH2 expression was observed in 1 of 21 PD-L1–positive tumors. Conclusions: A subset of prostate cancer expresses PD-L1, which is not increased by Neo-AAPL treatment, indicating that combining Neo-AAPL treatment with PD-L1/PD-1 blockade may not be synergistic. Clin Cancer Res; 23(22); 6812–22. ©2017 AACR.

[1]  M. Hudson.  Human , 2018, Critical Theory and the Classical World.

[2]  F. Prall,et al.  The PD‐1 expressing immune phenotype of T cell exhaustion is prominent in the ‘immunoreactive’ microenvironment of colorectal carcinoma , 2017, Histopathology.

[3]  Y. Nordby,et al.  The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort , 2017, Oncotarget.

[4]  Charles G. Drake,et al.  Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer , 2016, Oncotarget.

[5]  M. Mino‐Kenudson.  Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer? , 2016, Cancer biology & medicine.

[6]  Srinivasan Vijayakumar,et al.  Do African-American men need separate prostate cancer screening guidelines? , 2016, BMC Urology.

[7]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[8]  Ya-jun Guo,et al.  Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse , 2016, Science Translational Medicine.

[9]  J. Mefford,et al.  Mutational Landscape of Aggressive Prostate Tumors in African American Men. , 2016, Cancer research.

[10]  Marius Ilie,et al.  Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients , 2016, Virchows Archiv.

[11]  B. Delahunt,et al.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System , 2015, The American journal of surgical pathology.

[12]  M. Mino‐Kenudson.  Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer? , 2016, Cancer biology & medicine.

[13]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[14]  C. Marquette,et al.  Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  H. Samaratunga,et al.  Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis , 2016, Targeted Oncology.

[16]  G. Kristiansen,et al.  The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer , 2015, Clinical Cancer Research.

[17]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[18]  M. Scott Lucia,et al.  Paucity of PD-L1 Expression in Prostate Cancer: Innate and Adaptive Immune Resistance , 2015, Prostate Cancer and Prostatic Disease.

[19]  E. Carosella,et al.  A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. , 2015, European urology.

[20]  G. Freeman,et al.  Combination cancer immunotherapy and new immunomodulatory targets , 2015, Nature Reviews Drug Discovery.

[21]  Ash A. Alizadeh,et al.  Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .

[22]  Ming-Sound Tsao,et al.  Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  Matteo Brunelli,et al.  Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers , 2015, PloS one.

[24]  A. Zoubeidi,et al.  PD-L1 is highly expressed in Enzalutamide resistant prostate cancer , 2014, Oncotarget.

[25]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[26]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[27]  J. Richie,et al.  Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[29]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[30]  M. L. Moore,et al.  Increased CD8+ T-cell function following castration and immunization is countered by parallel expansion of regulatory T cells. , 2012, Cancer research.

[31]  D. McNeel,et al.  Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. , 2010, Human immunology.

[32]  W. Isaacs,et al.  Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+ , 2009, The Prostate.

[33]  A. Mes-Masson,et al.  Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. , 2009, Journal of immunological methods.

[34]  T. Wilt,et al.  A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. , 2009, Cancer treatment reviews.

[35]  D. Kosec,et al.  Neonatal castration affects intrathymic kinetics of T-cell differentiation and the spleen T-cell level. , 2007, The Journal of endocrinology.

[36]  P. Mischel,et al.  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma , 2007, Nature Medicine.

[37]  T. Heng,et al.  Activation of Thymic Regeneration in Mice and Humans following Androgen Blockade , 2005, The Journal of Immunology.

[38]  C. Drake,et al.  Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. , 2005, Cancer cell.

[39]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.